The RASONQUE launch revenue dramatically exceeded expectations, but the company cautioned that EAP transition and waiting patients are finite early-launch dynamics. Monitor the trajectory of quarterly net product revenue as these one-time dynamics fade and as formal payer coverage policies develop. The Phase 3 RASolve 301 NSCLC readout anticipated in 2027 is the next major catalyst.
Drugs in focus
RVMD drug pipeline →daraxonrasib
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3 (completed with positive results) / pre-NDA
- Time to market
- NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
- Next catalyst
- None dated
What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.
Price Chart
Executive Summary
Revolution Medicines reported Q3 2026 results with RASONQUE (daraxonrasib) generating $197.6M in net product revenue in its first ~5 weeks post-FDA approval, far exceeding the $27.3M consensus. Net loss widened to $407.5M from $305.2M a year ago due to higher R&D and SG&A costs. The company reiterated full-year 2026 GAAP operating expense guidance of $2.1B-$2.2B.
Key Financial Metrics
Key Facts
- RASONQUE net product revenue of $197.6M in Q3 2026, reflecting ~5 weeks of commercial availability following FDA approval on August 26, 2026
- More than 5,000 unique patients received commercial RASONQUE from FDA approval through September 30, 2026
- Received positive CHMP opinion recommending marketing authorization of daraxonrasib in the European Union for metastatic pancreatic cancer
- FDA granted Breakthrough Therapy Designation for daraxonrasib + gemcitabine + nab-paclitaxel in treatment-naive metastatic pancreatic cancer
- Cash, cash equivalents and marketable securities were $3.7B as of September 30, 2026, excluding $250M received in October from Royalty Pharma funding
- Net loss of $407.5M for Q3 2026 vs $305.2M in Q3 2025; R&D expenses $417.1M vs $262.5M; SG&A $153.3M vs $52.8M
- Full-year 2026 GAAP operating expense guidance reiterated at $2.1B-$2.2B
Financial Impact
RASONQUE net product revenue of $197.6M in its first partial quarter of sales, compared to consensus revenue estimate of $27.3M
Risk Factors
- Early launch dynamics (EAP transition, waiting patients, channel stocking) may not be sustainable; Q3 results should not be viewed as indicative of longer-term trajectory
- Net loss continues to widen significantly as R&D and SG&A expenses scale with commercialization and pipeline expansion
- Dependence on successful international approvals and reimbursement in Europe and Japan for future revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447193 |
| Document: 0001193125-26-447193-index.html | 0001193125-26-447193 |
| Document: 0001193125-26-447193.txt | 0001193125-26-447193 |
| 8-K Data (Synthetic) | 0001193125-26-447193 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 Viewing No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers